Cocrystal Pharma Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment

Reuters09-12

<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma Inc. presented at the 2025 International Calicivirus Conference, highlighting their oral direct-acting antiviral CDI-988 for norovirus infection prevention and treatment. The presentation, led by Sam Lee, PhD, President and co-CEO, detailed the mechanism of action and results from Phase 1 study of CDI-988. Norovirus is identified as the leading cause of acute viral gastroenteritis, with no current treatments or vaccines available, representing a significant unmet medical need. Cocrystal's CDI-988 is described as a first-in-class antiviral with potential for both prevention and treatment of norovirus infections. The company is planning a human challenge study in 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566979184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566979184","market":"us","top_or_hot":-1,"title":"Cocrystal Pharma Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cocrystal Pharma Inc. presented at the 2025 International Calicivirus Conference, highlighting their oral direct-acting antiviral CDI-988 for norovirus infection prevention and treatment. The presentation, led by Sam Lee, PhD, President and co-CEO, detailed the mechanism of action and results from Phase 1 study of CDI-988. Norovirus is identified as the leading cause of acute viral gastroenteritis, with no current treatments or vaccines available, representing a significant unmet medical need. Cocrystal's CDI-988 is described as a first-in-class antiviral with potential for both prevention and treatment of norovirus infections. The company is planning a human challenge study in 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cocrystal Pharma Inc. presented at the 2025 International Calicivirus Conference, highlighting their oral direct-acting antiviral CDI-988 for norovirus infection prevention and treatment. The presentation, led by Sam Lee, PhD, President and co-CEO, detailed the mechanism of action and results from Phase 1 study of CDI-988. Norovirus is identified as the leading cause of acute viral gastroenteritis, with no current treatments or vaccines available, representing a significant unmet medical need. Cocrystal's CDI-988 is described as a first-in-class antiviral with potential for both prevention and treatment of norovirus infections. The company is planning a human challenge study in 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL4mRWwv:1","article_id":"2566979184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566979184","pubTimestamp":1757679180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cocrystal Pharma Inc. presented at the 2025 International Calicivirus Conference, highlighting their oral direct-acting antiviral CDI-988 for norovirus infection prevention and treatment. The presentation, led by Sam Lee, PhD, President and co-CEO, detailed the mechanism of action and results from Phase 1 study of CDI-988. Norovirus is identified as the leading cause of acute viral gastroenteritis, with no current treatments or vaccines available, representing a significant unmet medical need. Cocrystal's CDI-988 is described as a first-in-class antiviral with potential for both prevention and treatment of norovirus infections. The company is planning a human challenge study in 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","COCP":"Cocrystal Pharma, Inc."},"translate_title":"Cocrystal Pharma Inc.推出用于预防和治疗诺如病毒的突破性抗病毒CDI-988","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"Cocrystal Pharma Inc. Unveils Presentation on Breakthrough Antiviral CDI-988 for Norovirus Prevention and Treatment\n    \n\n        Cocrystal Pharma Inc. presented at the 2025 International Calicivirus Conference, highlighting their oral direct-acting antiviral CDI-988 for norovirus infection prevention and treatment. The presentation, led by Sam Lee, PhD, President and co-CEO, detailed the mechanism of action and results from Phase 1 study of CDI-988. Norovirus is identified as the leading cause of acute viral gastroenteritis, with no current treatments or vaccines available, representing a significant unmet medical need. Cocrystal's CDI-988 is described as a first-in-class antiviral with potential for both prevention and treatment of norovirus infections. The company is planning a human challenge study in 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566979184","isCrawlerRequest":true}